Stocks moved sharply across sectors on the back of company-specific earnings and regulatory updates, with investors weighing guidance, cash flow and trial results. Several names jumped after results topped expectations or won key approvals, while others slid as outlooks disappointed or products failed in clinical studies.
Key takeaways
- Shares of IES Holdings rose more than 30% after better-than-expected quarterly results, alongside a newly approved two-for-one split.
- GoDaddy shares fell 20% after guidance failed to meet investor expectations, despite full-year free cash flow being broadly in line.
- Amazon surged 15% on stronger-than-expected revenue and accelerated cloud growth, signaling improving momentum in its web services business.
- Veracyte dropped 24% as investors reacted to results that topped consensus but failed to persuade on full-year revenue guidance quality and overall positioning.
- Replimune Group jumped over 94% after a Food and Drug Administration advisory panel backed the company’s RP1 trial results for a skin cancer indication.
What drove the biggest moves
IES Holdings gained over 30% after reporting better-than-expected quarterly results. The stock also received a boost from corporate actions: its board approved a two-for-one split of common stock to be paid as a stock dividend, a move that can affect shareholder perception and liquidity even before fundamentals change.
GoDaddy fell 20% as investors focused on the company’s outlook. The business reaffirmed full-year free cash flow of about $1.8 billion, roughly aligned with FactSet consensus of $1.81 billion, but the quarter and revenue range expectations did not fully satisfy the market. New data showed cash flow for the latest quarter came in below consensus, and full-year revenue guidance of $5.215 billion to $5.255 billion landed close to, but not decisively above, estimates.
Newell Brands climbed 11% after lifting full-year earnings guidance to 73 cents to 77 cents per share, above its prior forecast of 56 cents to 60 cents. The updated outlook also surpassed FactSet consensus of 58 cents per share, giving investors a clearer line of sight on profitability recovery and earnings power.
In tech and cloud, Amazon stood out with a 15% rally after reporting better-than-expected revenue and cloud growth. Data cited in the report showed Amazon Web Services revenue expanded 37% year over year, exceeding expectations for 31% growth and marking the unit’s fastest growth in 18 quarters—an important benchmark for investors tracking cloud demand and competitive positioning.
Apple shares dropped more than 9% despite stronger-than-expected fiscal third-quarter revenue, as the market fixated on iPhone momentum. The company’s iPhone sales rose 22% year over year, but investors appeared to question broader demand signals and the sustainability of the quarter’s strength.
Energy and consumer companies react to earnings
Chevron gained 1.6% after reporting better-than-expected earnings and revenue for the second quarter. The company recorded $12.1 billion in net income, nearly quadruple the prior-year period, underscoring improved profitability that can support investor confidence in capital allocation.
ExxonMobil fell 2% after posting weaker-than-expected earnings. The report said the company earned an adjusted $3.52 per share versus analyst expectations of $3.60 per share, a gap that was enough to pressure the stock despite ongoing investor focus on refining margins, upstream performance, and costs.
Jersey Mike’s rose 6% following its public debut. Shares opened at $21 per share, down from its $23 offering price, and the stock ended the debut day down 6%, reflecting a cautious opening that later stabilized for at least one trading session.
In industrials, SPX Technologies rose 14% after second-quarter results exceeded analyst expectations. The company also raised its full-year earnings and revenue outlook, suggesting that margin and demand assumptions were stronger than previously modeled by the Street.
Biotech, diagnostics and regulatory catalysts
Replimune Group surged over 94% after an FDA advisory panel voted in favor of the company’s RP1 drug trial results for a type of skin cancer. Wedbush Securities upgraded the stock to outperform from neutral following the decision, highlighting how regulatory pathways and committee feedback can quickly shift probability-weighted valuations in clinical-stage oncology.
Veracyte declined 24% despite exceeding analyst expectations on adjusted earnings and revenue. The stock fell after the company also raised full-year revenue guidance but failed to impress investors, indicating that the market may have been seeking either stronger growth signals or greater confidence in demand durability.
Moderna shares fell 1% even though second-quarter results beat expectations. The report said the company posted a loss of $1.97 per share on revenue of $145 million, versus analysts’ expectation of a $2.03 loss on revenue of $102.9 million. Full-year revenue guidance was also above expectations, but the stock’s decline suggests investors were weighing more than just near-term beats—potentially expectations around longer-term demand, pipeline progress, or cost and forecasting assumptions.
In addition, Novo Nordisk dropped 9% after Phase 3 trial results for ziltivekimab failed to reduce major cardiovascular events versus placebo. For investors, negative late-stage outcomes can materially alter probability of success and future revenue potential, regardless of other pipeline activity.
Market reaction beyond earnings beats
Verifiable selloffs showed that “beat” results do not always translate into upside. Coinbase shares slid more than 12% after posting its third straight quarterly loss, reporting a loss of $359.5 million, or $1.36 per share, with revenue of $1.22 billion coming in below the $1.31 billion estimate cited in the report.
Reddit shares dropped 22%, reflecting concerns about search-referral traffic from Google. CEO Steve Huffman said search referrals were “choppy” in the quarter. While the company reported second-quarter earnings that beat on the top and bottom lines and issued guidance that exceeded expectations, the market reaction suggested that traffic quality and user acquisition economics remained key uncertainties.
Across the tape, the most significant winners tended to combine operational upside with clearer forward expectations—raised guidance, stronger growth metrics or regulatory momentum. Losers often faced a mismatch between reported performance and the market’s baseline assumptions, particularly around cash flow, guidance credibility, or clinical efficacy.
Investors will likely keep an eye on what these results imply for the broader earnings cycle: whether guidance raises persist, how investors interpret cash flow and revenue quality, and whether upcoming regulatory and clinical readouts shift probability expectations. With more corporate updates and macro catalysts typically in the pipeline, next attention will be on continued company guidance and upcoming data releases that can affect discount rates.
